



## Breast Cancer Radiotherapy: The State of the Art

Guest Editor:

**Dr. Youlia Kirova**

Associate Professor of Radiation  
Oncology UVSQ, Department of  
Radiation Oncology, Institut  
Curie, 75005 Paris, France

Deadline for manuscript  
submissions:

**closed (31 January 2022)**

### Message from the Guest Editor

Dear Colleagues,

Adjuvant breast radiotherapy improves local control and reduces cancer-specific mortality; however first-generation techniques were associated with an increased risk of long term toxicity, a direct consequence of the wide irradiation fields which were used at that time and which exposed substantial cardiac volumes. Breast radiotherapy has fortunately evolved; currently, cardiac sparing can be efficiently achieved thanks to state-of-the-art techniques such as rotational intensity modulated radiation therapy (IMRT) or protontherapy. New molecules are arriving in the breast cancer treatment and it is important to know the efficacy and toxicity of these associations. This Special Issue is trying to respond of some of this questions.

Prof. Youlia Kirova  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)